Halozyme Therapeutics (NASDAQ:HALO) Issues FY24 Earnings Guidance

Halozyme Therapeutics (NASDAQ:HALO) updated its FY24 earnings guidance on Tuesday. The company provided EPS guidance of $3.55-3.90 for the period, compared to the consensus EPS estimate of $3.52. The company issued revenue guidance of $915-985 million, compared to the consensus revenue estimate of $954.43 million.

Wall Street Analysts Forecast Growth

Several research firms have recently commented on HALO. TD Cowen assumed coverage on Halozyme Therapeutics in a report on Thursday, February 29th. They issued an outperform rating and a $54.00 price objective for the company. StockNews.com upgraded Halozyme Therapeutics from a hold rating to a buy rating in a research report on Friday, February 23rd. TheStreet cut Halozyme Therapeutics from a b- rating to a c+ rating in a research report on Monday, January 22nd. Benchmark reissued a buy rating and set a $50.00 target price on shares of Halozyme Therapeutics in a research note on Tuesday, April 16th. Finally, JMP Securities lowered their price target on shares of Halozyme Therapeutics from $72.00 to $71.00 and set a market outperform rating on the stock in a report on Wednesday. One research analyst has rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of Moderate Buy and an average price target of $53.14.

Halozyme Therapeutics Price Performance

Shares of NASDAQ:HALO traded down $0.67 on Friday, reaching $43.17. The company’s stock had a trading volume of 329,127 shares, compared to its average volume of 1,210,315. The company has a market cap of $5.48 billion, a P/E ratio of 20.78, a PEG ratio of 0.47 and a beta of 1.26. The company has a 50-day simple moving average of $40.17 and a 200 day simple moving average of $38.05. Halozyme Therapeutics has a 52-week low of $31.86 and a 52-week high of $45.00. The company has a debt-to-equity ratio of 17.89, a quick ratio of 5.50 and a current ratio of 6.64.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Tuesday, February 20th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.77 by ($0.02). Halozyme Therapeutics had a net margin of 33.96% and a return on equity of 248.20%. The business had revenue of $230.04 million for the quarter, compared to analysts’ expectations of $235.25 million. As a group, equities research analysts anticipate that Halozyme Therapeutics will post 3.43 EPS for the current fiscal year.

Insider Buying and Selling

In other news, SVP Michael J. Labarre sold 10,000 shares of the stock in a transaction that occurred on Tuesday, March 12th. The shares were sold at an average price of $41.64, for a total value of $416,400.00. Following the completion of the sale, the senior vice president now owns 156,558 shares of the company’s stock, valued at approximately $6,519,075.12. The transaction was disclosed in a filing with the SEC, which is accessible through this link. In the last three months, insiders have sold 30,000 shares of company stock worth $1,196,800. Insiders own 2.70% of the company’s stock.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.